Key Results
Surprisingly, we found that oral NVP-BHG712 treatment significantly
reduced bone loss in postmenopausal mice. In vitro osteoclast culture,
it was found that this effect was achieved by inhibiting osteoclast
differentiation and bone resorption. Meanwhile, NVP-BHG712 significantly
decreased the expression of genes related to osteoclast differentiation,
including CTSK, MMP9, CTR, IP3R1, IP3R3, and OC-STAMP.